RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyAn independent opinion from a Big Biotech oncolcolgy chief scientific officer saying that a M&A valued between US$5 Billion and US$10 Billion is 'good vaue' for the acquiring Big Pharma company confirms what I have been saying for quite awhile.
This notwithstanding ONCY's fair value is between US$10 Billion and US$15 Billion, given the shift in time and the increased competion that Big Pharma is facing with a looming patent cliff and their need to supplement their oncology product pipleines with novel late-stage cancer killing drugs like ONCY's pelareorep that is a late-stage Phase 3 ready drug.